Resilient Merck stock holds close to a 12-month high on oncology strength
Published on 08/18/2026 at 09:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. (US58933Y1055) stock is trading close to a new 12-month high in mid-August 2026, with recent quotes reported near $135.84 on the New York Stock Exchange as of August 17, 2026 and a market value stated at $335.8 billion. An article summarizing recent market data notes that this level leaves the shares just below a 12-month high of $135.97, underscoring how the stock has moved into the upper end of its yearly trading range.
Q2 earnings beat underpins the rally
Merck’s latest quarterly results have been a key driver of this strong share performance. A market report on recent 52-week highs describes how Merck’s stock closed up 0.09 percent after it delivered a robust second-quarter earnings beat, helped by positive clinical trial momentum in its oncology portfolio.
In that same coverage, Merck’s Q2 2026 revenue is cited at $16.61 billion, with growth of 5 percent year over year and performance above Wall Street expectations. The report attributes the increase to continued strength in oncology treatments, particularly the immunotherapy medicine Keytruda, alongside growth in animal health and newer products, giving investors a clearer sense of how diversified product demand is supporting topline expansion in the most recent quarter.
The article also points to Merck’s current full-year 2026 revenue forecast, which is stated as a range of $65.8 billion to $67 billion. This guidance frames investor expectations for the rest of the year and implies that if the company can sustain mid-single digit growth from the second quarter, it has a realistic path to reach the upper end of that range.
Valuation and dividend sustainability in focus
Beyond the earnings beat, valuation and income characteristics have become key talking points for Merck’s shareholders. A detailed valuation analysis notes that Merck trades at a price of $135.84 compared with a GF Value of $119.85, implying that the shares are 13.3 percent above that fair-value estimate.
According to the same analysis, Merck’s stock also supports an annualized dividend payout of $3.40 per share. When set against the $135.84 recent share price as of August 17, 2026, this translates into a forward dividend yield of 2.5 percent, offering investors a mix of capital appreciation and income. The assessment suggests that the yield is sustainable but that the company’s payout strategy will likely remain under scrutiny as management balances investment in the oncology pipeline and other growth areas with continued cash returns to shareholders.
The valuation note highlights how Merck’s current trading level represents a modest premium to certain fair-value models, reflecting market confidence in its pipeline rather than near-term earnings alone. When aligned with Q2 revenue growth of 5 percent year over year, the implied 13.3 percent valuation premium indicates that investors are willing to pay a higher multiple for the stability and potential of its oncology franchise.
Analyst upgrade supports momentum
The same valuation-focused coverage references a recent analyst action that has contributed to sentiment around the stock. On August 17, 2026, Merck is described as having received an upgrade from Neutral to Outperform, with the associated price target raised from $120 to $143. This move, coming while the shares trade in the mid-$130s, suggests that the analyst sees further upside from current levels if the company continues to execute on its growth strategy and deliver on its revenue guidance.
For investors, the combination of a Q2 2026 earnings beat, a clear full-year revenue range of $65.8 billion to $67 billion, a dividend yield of 2.5 percent, and an upgraded rating with a new $143 price target paints a picture of a company where both fundamentals and external views are supportive of the recent share performance. The quantified comparison between the current $135.84 price and the $143 target also gives a concrete sense of how much potential upside certain market observers see relative to today’s valuation.
One-year performance and technical levels
Recent market data compiled on August 17, 2026 show Merck stock quoted at $135.84 in regular trading, modestly above a prior closing price of $135.78 on August 14, 2026. That change corresponds to a daily percentage gain of 0.23 percent in the latest regular session, illustrating how the stock has been edging higher rather than moving in sharp swings. The same dataset reports that the shares’ 12-month high stands at $135.97, with the current quote sitting just below that threshold, reinforcing the perception of a resilient trend.
The one-year performance context is also noteworthy. The recent article describes how these levels imply a one-year total price gain of 69.7 percent as of August 17, 2026, a substantial appreciation that outpaces many large-cap peers over the same timeframe. This quantified comparison between current price and the level one year earlier helps explain why valuation metrics, including the 13.3 percent premium to GF Value, have come under closer review.
Technical snapshots from a dedicated quote and analysis page list Merck’s stock at $136.00 at the close of August 17, 2026, with a daily change of 0.12 percent and the venue described as the New York Stock Exchange. While minor differences in intraday readings are common, the consistent indication that the shares are trading in the mid-$130s underscores that the stock is holding near the top of its recent range rather than pulling back sharply.
Keytruda remains a central driver
Operationally, Merck’s oncology franchise continues to anchor its growth story, particularly through Keytruda. The Q2 2026 earnings coverage credits ongoing strength in oncology, led by this flagship medicine, as a primary reason for the 5 percent year-over-year revenue increase to $16.61 billion. The product’s performance not only boosts quarterly sales but also underpins the confidence embedded in the full-year revenue guidance of $65.8 billion to $67 billion.
Recent commentary on Merck’s stock points out that this oncology-led growth sits alongside contributions from animal health and newer products, painting a picture of a diversified business model where no single segment dominates to the exclusion of others. However, the recurring mention of Keytruda as a key contributor indicates that developments in cancer immunotherapy will remain central to investor debate around Merck’s valuation and long-term prospects.
Flagship oncology product: Keytruda
Within Merck’s portfolio, Keytruda stands out as a representative product that illustrates the company’s strategic emphasis on oncology. The Q2 2026 report referenced in market coverage describes how continued demand for Keytruda helped drive the $16.61 billion in quarterly revenue, reinforcing the medicine’s role as a cornerstone therapy in multiple cancer indications.
Keytruda’s clinical trajectory, including ongoing trials and regulatory submissions, contributes to the positive clinical trial momentum highlighted in the discussion of Merck’s 52-week high. As new indications are pursued and approved, each adds incremental revenue and potentially extends the product’s lifecycle, supporting the company’s ability to maintain or increase its full-year revenue guidance in the $65.8 billion to $67 billion range.
Closing view on Merck stock and current market data
As of August 17, 2026, 3:59 p.m. ET, recent market data present Merck stock at a price of $135.84 in regular New York Stock Exchange trading, with the shares sitting just below a 12-month high of $135.97 and reflecting a one-year price gain of 69.7 percent. For US retail investors, these figures frame Merck as a large-cap healthcare name whose current valuation blends earnings growth, a 2.5 percent dividend yield based on a $3.40 per-share payout, and sustained enthusiasm for its oncology pipeline.
Fact box
Company: Merck & Co., Inc.
ISIN: US58933Y1055
Ticker: MRK
Exchange: New York Stock Exchange
Price (as of August 17, 2026, 3:59 p.m. ET): $135.84 USD
Market cap: $335.8 billion (as of August 17, 2026)
Sector / Industry: Health care / Pharmaceuticals
Index membership: S&P 500
